Abstract:Abstract Background Long non-coding RNAs are important regulators of gene expression and diverse biological processes. Their aberrant expression contributes to a verity of diseases including cancer development and progression, providing them with great potential to be diagnostic and prognostic biomarkers and therapeutic targets. Therefore, they can have a key role in personalized cancer medicine. This review aims at introducing possible strategies to target long ncRNAs therapeutically in cancer. Also, chemical modification of nucleic acid-based therapeutics to improve their pharmacological properties is explained. Then, approaches for the systematic delivery of reagents into the tumor cells or organs are briefly discussed, followed by describing obstacles to the expansion of the therapeutics. Main text Long ncRNAs function as oncogenes or tumor suppressors, whose activity can modulate all hallmarks of cancer. They are expressed in a very restricted spatial and temporal pattern and can be easily detected in the cells or biological fluids of patients. These properties make them excellent targets for the development of anticancer drugs. Targeting methods aim to attenuate oncogenic lncRNAs or interfere with lncRNA functions to prevent carcinogenesis. Numerous strategies including suppression of oncogenic long ncRNAs, alternation of their epigenetic effects, interfering with their function, restoration of downregulated or lost long ncRNAs, and recruitment of long ncRNAs regulatory elements and expression patterns are recommended for targeting long ncRNAs therapeutically in cancer. These approaches have shown inhibitory effects on malignancy. In this regard, proliferation, migration, and invasion of tumor cells have been inhibited and apoptosis has been induced in different cancer cells in vitro and in vivo. Downregulation of oncogenic long ncRNAs and upregulation of some growth factors (e.g., neurotrophic factor) have been achieved. Conclusions Targeting long non-coding RNAs therapeutically in cancer and efficient and safe delivery of the reagents have been rarely addressed. Only one clinical trial involving lncRNAs has been reported. Among different technologies, RNAi is the most commonly used and effective tool to target lncRNAs. However, other technologies need to be examined and further research is essential to put lncRNAs into clinical practice.

Non-coding RNAs as therapeutic targets in cancer and its clinical application

Dysregulation Of Long Non-Coding Rna In Breast Cancer: An Overview Of Mechanism And Clinical Implication

The Role of Non-Coding RNA in Tumorigenesis, Development,diagnosis and Treatment

Noncoding RNAs in tumorigenesis and tumor therapy

Targeting long non-coding RNAs in cancers: progress and prospects

Comprehensive review for non-coding RNAs: From mechanisms to therapeutic applications

Long Noncoding RNA: Its Partners and Their Roles in Cancer

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

Targeting non-coding RNAs to overcome cancer therapy resistance

LncRNAs and CircRNAs in cancer

Strategies to target long non-coding RNAs in cancer treatment: progress and challenges

Non-Coding RNA in Tumor Cells and Tumor-Associated Myeloid Cells-Function and Therapeutic Potential

Non-coding RNAs in disease: from mechanisms to therapeutics

Potential therapies for non-coding RNAs in breast cancer

Role of noncoding RNAs and untranslated regions in cancer: A review

Curcumin Targeting Non-Coding RNAs in Colorectal Cancer: Therapeutic and Biomarker Implications

Long Non-Coding RNAs: an Emerging Powerhouse in the Battle Between Life and Death of Tumor Cells

Regulation of Angiogenesis by Non-Coding RNAs in Cancer

Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA

MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside

Potential Regulatory Roles of MicroRNAs and Long Noncoding RNAs in Anticancer Therapies